81 related articles for article (PubMed ID: 22139909)
21. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
Lassiter G; Bergeron C; Guedry R; Cucarola J; Kaye AM; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
Curr Oncol; 2021 Jan; 28(1):640-660. PubMed ID: 33494319
[TBL] [Abstract][Full Text] [Related]
22. IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies.
Kirchhoff D; Stelte-Ludwig B; Lerchen HG; Wengner AM; Ahsen OV; Buchmann P; Märsch S; Mahlert C; Greven S; Dietz L; Erkelenz M; Zierz R; Johanssen S; Mumberg D; Sommer A
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233768
[TBL] [Abstract][Full Text] [Related]
23. Thiadiazole derivatives as anticancer agents.
Szeliga M
Pharmacol Rep; 2020 Oct; 72(5):1079-1100. PubMed ID: 32880874
[TBL] [Abstract][Full Text] [Related]
24. Tissue engineered models of healthy and malignant human bone marrow.
Chramiec A; Vunjak-Novakovic G
Adv Drug Deliv Rev; 2019 Feb; 140():78-92. PubMed ID: 31002835
[TBL] [Abstract][Full Text] [Related]
25. High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma.
Li X; Liu M; Zhang Z; Zhang L; Liang X; Sun L; Zhong D
Thorac Cancer; 2019 May; 10(5):1103-1110. PubMed ID: 30907518
[TBL] [Abstract][Full Text] [Related]
26. A New Way to Treat Brain Tumors: Targeting Proteins Coded by Microcephaly Genes?: Brain tumors and microcephaly arise from opposing derangements regulating progenitor growth. Drivers of microcephaly could be attractive brain tumor targets.
Lang PY; Gershon TR
Bioessays; 2018 May; 40(5):e1700243. PubMed ID: 29577351
[TBL] [Abstract][Full Text] [Related]
27. Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation.
Wang Y; Wu X; Du M; Chen X; Ning X; Chen H; Wang S; Liu J; Liu Z; Li R; Fu G; Wang C; McNutt MA; Zhou D; Yin Y
Oncotarget; 2017 Jun; 8(26):42510-42524. PubMed ID: 28489567
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells.
Norris EJ; DeStephanis D; Tunquist B; Usmani S; Ganapathi R; Ganapathi M
Blood Cancer J; 2016 Oct; 6(10):e480. PubMed ID: 27716742
[No Abstract] [Full Text] [Related]
29. KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL.
Zhu L; Xiao F; Yu Y; Wang H; Fang M; Yang Y; Sun H; Wang L; Sheng Y
Anticancer Drugs; 2016 Oct; 27(9):863-72. PubMed ID: 27379929
[TBL] [Abstract][Full Text] [Related]
30. Targeting the Mitotic Catastrophe Signaling Pathway in Cancer.
Mc Gee MM
Mediators Inflamm; 2015; 2015():146282. PubMed ID: 26491220
[TBL] [Abstract][Full Text] [Related]
31. Structure-Guided Design of Novel l-Cysteine Derivatives as Potent KSP Inhibitors.
Ogo N; Ishikawa Y; Sawada J; Matsuno K; Hashimoto A; Asai A
ACS Med Chem Lett; 2015 Sep; 6(9):1004-9. PubMed ID: 26396688
[TBL] [Abstract][Full Text] [Related]
32. The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma.
Venere M; Horbinski C; Crish JF; Jin X; Vasanji A; Major J; Burrows AC; Chang C; Prokop J; Wu Q; Sims PA; Canoll P; Summers MK; Rosenfeld SS; Rich JN
Sci Transl Med; 2015 Sep; 7(304):304ra143. PubMed ID: 26355032
[TBL] [Abstract][Full Text] [Related]
33. Interphase microtubules: chief casualties in the war on cancer?
Ogden A; Rida PC; Reid MD; Aneja R
Drug Discov Today; 2014 Jul; 19(7):824-9. PubMed ID: 24201225
[TBL] [Abstract][Full Text] [Related]
34. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
Hollebecque A; Deutsch E; Massard C; Gomez-Roca C; Bahleda R; Ribrag V; Bourgier C; Lazar V; Lacroix L; Gazzah A; Varga A; de Baere T; Beier F; Kroesser S; Trang K; Zenke FT; Klevesath M; Soria JC
Invest New Drugs; 2013 Dec; 31(6):1530-8. PubMed ID: 24077982
[TBL] [Abstract][Full Text] [Related]
35. Kinesin-5: cross-bridging mechanism to targeted clinical therapy.
Wojcik EJ; Buckley RS; Richard J; Liu L; Huckaba TM; Kim S
Gene; 2013 Dec; 531(2):133-49. PubMed ID: 23954229
[TBL] [Abstract][Full Text] [Related]
36. A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells.
Aljitawi OS; Li D; Xiao Y; Zhang D; Ramachandran K; Stehno-Bittel L; Van Veldhuizen P; Lin TL; Kambhampati S; Garimella R
Leuk Lymphoma; 2014 Feb; 55(2):378-91. PubMed ID: 23566162
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic role of kinesin proteins and targeting kinesin therapy.
Liu X; Gong H; Huang K
Cancer Sci; 2013 Jun; 104(6):651-6. PubMed ID: 23438337
[TBL] [Abstract][Full Text] [Related]
38. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
Khoury HJ; Garcia-Manero G; Borthakur G; Kadia T; Foudray MC; Arellano M; Langston A; Bethelmie-Bryan B; Rush S; Litwiler K; Karan S; Simmons H; Marcus AI; Ptaszynski M; Kantarjian H
Cancer; 2012 Jul; 118(14):3556-64. PubMed ID: 22139909
[TBL] [Abstract][Full Text] [Related]
39. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA
Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345
[TBL] [Abstract][Full Text] [Related]
40. Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
Infante JR; Patnaik A; Verschraegen CF; Olszanski AJ; Shaheen M; Burris HA; Tolcher AW; Papadopoulos KP; Beeram M; Hynes SM; Leohr J; Lin AB; Li LQ; McGlothlin A; Farrington DL; Westin EH; Cohen RB
Cancer Chemother Pharmacol; 2017 Feb; 79(2):315-326. PubMed ID: 28097385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
